COVID-19 Vaccinology Update: Will New Variants Necessitate New Vaccines?

Sign in to view your progression
Program Overview Progr...
Learning Objectives Learn...
Target Audience Targe...
References Refer...
Disclosure/Disclaimer Discl...

Activity Title: COVID-19 Vaccinology Update: Will New Variants Necessitate New Vaccines 

Release Date: March 5, 2021

Estimated Time to Complete Activity: 55 minutes

Statement of Need:

The emergence and spread of COVID-19 variants raises new questions and scientists must debate whether the variants undercut the effectiveness of first-generation COVID-19 vaccines. The new strains of  SARS-CoV-2, first identified in the United Kingdom (B.1.1.7), Brazil (P.1) and South Africa (B.1.351), have developed a substantial number of mutations, especially in the S-protein, that seem to reduce the effects of antibodies crucial to fending off infection. This webinar is a follow up to ISID’s webinar on “COVID-19 Vaccinology Update: Development, Use and Effect on Public Health” released in January 2021. Prof. Malavige and Prof. Madhi will discuss the implications of these mutations on vaccine response and how vaccine manufacturers plan to update their vaccines to better target the emerging variants. Additionally, Prof. Madhi will discuss new results from phase 3 trials and what it will take to achieve herd immunity. 

Faculty:

Neelika Malavige is a Professor and head of the Department of Immunology and Molecular Medicine, the Director of the Centre for Dengue Research, University of Sri Jayewardenepura, Sri Lanka and an academic visitor at the MRC Human Immunology Unit, University of Oxford. She is also a Fellow of the Royal College of Physicians, London and a Fellow of the Royal College of Pathologists, UK. 

Shabir A. Madhi is currently the Dean of the Faculty of Health Sciences at the Wits University. His former positions include Professor of Vaccinology in the School of Pathology at the University of the Witwatersrand and Director of the world-renowned Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit (VIDA). Madhi is the National Research Foundation/Department of Science and Innovation SARChI Chair in Vaccine Preventable Diseases and he is Co-Director of African Leadership in Vaccinology Expertise (ALIVE). He chairs the National Advisory Group on Immunization in South Africa. His qualifications include MBBCh (Wits), MMed (Wits), FCPaeds(SA), Ph.D.

Technical Requirements

This site and its activities are best viewed using the latest versions of the Chrome, Edge, Firefox and Safari browsers. For interactive content a broadband connection is required. For CME/CE activities featuring audio you need a sound card and speakers.

Our activities may require JavaScript to be enabled on your computer. If you are having difficulty viewing pop-up windows, click here for instructions on enabling JavaScript.

Contact Information

If you have questions about this CME activity, please contact The International Society for Infectious Diseases at  info@isid.org.

For technical support issues, please contact Multilearning at support@multilearning.com

Upon completion of this module, participants should be able to:

  • Discuss the emergence and spread of COVID-19 variants and whether the variants undercut the effectiveness of first-generation COVID-19 vaccines
  • Describe the new strains of  SARS-CoV-2, first identified in the United Kingdom (B.1.1.7), Brazil (P.1) and South Africa (B.1.351), that have developed a substantial number of mutations, especially in the S-protein, that seem to reduce the effects of antibodies crucial to fending off infection
  • Discuss the implications of mutations on vaccine response and how vaccine manufacturers plan to update their vaccines to better target the emerging variants. 

The target audience for this module is physicians, nurses, public health officials, researchers, immunization officers, and other health professionals.

Shinde V, Bhikha S, Hoosain Z, et al; 2019nCoV-501 Study Group. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021 May 5;384(20):1899–909. doi: 10.1056/NEJMoa2103055. https://pubmed.ncbi.nlm.nih.gov/33951374/

Madhi SA, Baillie V, Cutland CL, et al; NGS-SA Group Wits–VIDA COVID Group. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021 Mar 16:NEJMoa2102214. doi: 10.1056/NEJMoa2102214.  https://pubmed.ncbi.nlm.nih.gov/33725432/

McDonald I, Murray SM, Reynolds CJ, Altmann DM, Boyton RJ. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. NPJ Vaccines. 2021 May 13;6(1):74. doi: 10.1038/s41541-021-00336-1. https://pubmed.ncbi.nlm.nih.gov/33986272/

Emary KRW, Golubchik T, Aley PK, et al; COVID-19 Genomics UK consortium; AMPHEUS Project; Oxford COVID-19 Vaccine Trial Group. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021 Apr 10;397(10282):1351-1362. doi: 10.1016/S0140-6736(21)00628-0.  https://pubmed.ncbi.nlm.nih.gov/33798499/

 

Disclosure Policy

In accordance with the EACCME Standards for Commercial Support, the International Society for Infectious Diseases (ISID) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. ISID  resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all our educational programs. Furthermore, ISID seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. ISID is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures:

The planners, reviewers, editors, staff, or other members at the International Society for Infectious Diseases who control content have no relevant financial relationships to disclose. 

ISID Knowledge Exchange and E-Learning Platform Organizing Committee members are listed here along with Committee members’ disclosure forms. 

Faculty Disclosures:

Professor Neelika Malavige
Affiliation/Financial Interest and Name of Commercial Company
Receipt of honoraria or consultation fees: Sun Pharma (India)

Professor Shabir Madhi
Affiliation/Financial Interest and Name of Commercial Company
Grants/Research Support: Bill and Melinda Gates Foundation, South Africa Medical Research Council, Novavax
Sponsored Speakers Bureau: Cipla, Novartis

Disclosure of Unlabeled Use

The International Society for Infectious Diseases  requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. ISID does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Disclaimer

The International Society for Infectious Diseases presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The International Society for Infectious Diseases, and the former commercial supporter assume no liability for the information herein.

Copyright Information

Copyright © 2021 by the International Society for Infectious Diseases. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

•  The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.

•  Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without the International Society for Infectious Diseases' prior written permission.

Privacy Policy

The International Society for Infectious Diseases protects the privacy of personal and other information regarding participants and educational collaborators. The International Society for Infectious Diseases will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The International Society for Infectious Diseases maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

Additional information regarding the International Society for Infectious Diseases Privacy Policy and ISID’s Knowledge Exchange and E-Learning Platform Privacy Policy can be viewed at https://isid.org/privacy-policy/ and https://exchange.isid.org/isid/legal/terms-and-conditions.

 

COVID-19 Vaccinology Update: Will New Variants Necessitate New Vaccines?

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies